Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

119results about How to "Promote cell proliferation" patented technology

Hybrid biologic-synthetic bioabsorbable scaffolds

A bioprosthetic device is provided for soft tissue attachment, reinforcement, and or reconstruction. The device comprises a naturally occurring extracellular matrix portion and a three-dimensional synthetic portion. In illustrated embodiments, the naturally occurring extracellular matrix portion comprises layers of small intestine submucosa, and the three-dimensional synthetic portion comprises a foam or a three-dimensional mesh, textile, or felt.
Owner:DEPUY SYNTHES PROD INC

Apparatus and method for wound, cavity, and bone treatment

InactiveUS20100030132A1Quicker wound closureSafer wound care environmentElectrolysis componentsCannulasNeed treatmentBiomedical engineering
The present invention provides a treatment apparatus. The apparatus contains a reservoir or generator for a treatment solution, a mechanism for delivering the treatment solution to a wound site, and a mechanism for applying the solution to a wound, tissue, bone or surgical cavity for treatment. The apparatus may apply the solution (e.g., a solution containing hypohalous acid) with, for example, an occlusive wound dressing, pulsative lavage device, hydrotherapy, hydrosurgical device, and / or ultrasound. A waste container may be operably connected to the apparatus for collecting waste from the wound by run-off, or by applying negative pressure (e.g. a vacuum). Because the apparatus of the invention can optionally be portable or mobile, the invention is suitable for use in hospitals and nursing homes, as well as for home wound care. The invention also provides a method for treating a wound (or other area needing treatment), and / or for reducing wound bioburden, by supplying a hypochlorous acid solution to the site, such as a wound colonized or infected with drug resistant bacteria, before, during, or after negative pressure wound therapy.
Owner:PURICORE

Hybrid biologic/synthetic porous extracellular matrix scaffolds

Methods of making a hybrid biologic / synthetic scaffold for repairing damaged or diseased tissue are provided. The methods include the step of suspending pieces of an extracellular matrix material in a liquid to form a slurry, and coating a synthetic mat with the slurry, or mixing or layering the slurry with a synthetic polymer solution. The liquid is subsequently driven off so as to form a foam. Porous implantable scaffolds fabricated by such a method are also disclosed.
Owner:DEPUY SYNTHES PROD INC

Use of effectors of glutaminyl and glutamate cyclases

ActiveUS20070191366A1Stimulate gastrointestinal tractPrevent proliferationBiocideNervous disorderCyclaseMedicine
The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
Owner:VIVORYON THERAPEUTICS NV

Hybrid biologic-synthetic bioabsorbable scaffolds

A bioprosthetic device is provided for soft tissue attachment, reinforcement, and or reconstruction. The device comprises a naturally occurring extracellular matrix portion and a synthetic portion.
Owner:DEPUY PROD INC

Hybrid biologic-synthetic bioabsorbable scaffolds

A bioprosthetic device is provided for soft tissue attachment, reinforcement, and or reconstruction. The device comprises a naturally occurring extracellular matrix portion and a synthetic portion.
Owner:DEPUY SYNTHES PROD INC

Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Owner:IMMATICS BIOTECHNOLOGIES GMBH

Monoclonal antibodies against her2 epitope and methods of use thereof

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.
Owner:MERSANA THERAPEUTICS INC

CIK cell, as well as preparation method and cell preparation thereof

The invention discloses a CIK cell, as well as a preparation method and a cell preparation thereof. The method for preparing the CIK cell comprises the following steps: placing a separated mononuclear cell in a culture fluid containing phytohemagglutinin; transplanting the mononuclear cell into a culture flask enveloped by antiCD3 monoclonal antibody and antiCD28 monoclonal antibody after the cell is cultured for 24 to 72 hours; and adding a culture fluid containing IL-1alpha and IL-2 into the culture flask to keep on culturing for 5 to 15 days, and separating the cells into different flasks to be cultured every 2 to 3 days. The CIK cell prepared by the method has the characteristics of obvious improved cell proliferation, great increase of CD8 cell proportion, wide antineoplastic spectrum and strengthened antineoplastic activity. The CIK cell and the cell preparation can effectively prevent the metastasis and the recrudescence for of postoperative patients with tumor, can be combined with chemicotherapy to effectively reduce toxic and side effects of the chemicotherapy, strengthens the survivability tolerance of the patients to improve healing efficacy, and can obviously prolong lifecycle to of end-stage patients so as to improve the life living quality.
Owner:上海德嘉生物科技有限公司 +1

Bioactive botanical cosmetic compositions and processes for their production

InactiveUS20110212190A1Inhibitory activityEnhance antiproteolytic activityCosmetic preparationsBiocideDermatologyBiological activity
The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin cosmetic applications.
Owner:ISP INVESTMENTS LLC

Method for selective depletion of cd137 positive cells using Anti-cd137 antibody-toxin complex

InactiveUS20110177104A1Promote cell proliferationEffectively prevent and treat diseasesAntipyreticAnalgesicsDiseaseCD137
The present invention relates to method for depletion of CD137 positive cells using an anti-CD137 antibody-toxin complex, and more particularly, to a method for selective depletion of CD137 positive cells, comprising the step of contacting an anti-CD137 antibody-toxin complex with the CD137 positive cells. The method for selective depletion of CD137 positive cells in accordance with the present invention can be useful to prevent or treat various diseases including immune diseases mediated by the activation of the CD137 positive cells because this method is excellent in delivering a complex of an anti-CD137 antibody, specific to CD137 molecules, and a toxin to CD137 expressing cells and selectively killing the CD137 positive cells alone and is also excellent in suppressing cell proliferation.
Owner:UNIV OF ULSAN FOUND FOR IND COOPERATION

Novel recombinant poxvirus composition and uses thereof

The present invention provides a recombinant pox virus composition comprising a nucleic acid sequence encoding chemokines as costimulatory molecules. The present invention further provides a host cell, a host animal, and a pharmaceutical composition comprising the recombinant pox virus composition. Also provided is a method for treating or preventing a neoplasm or infectious disease in a subject, using the pox virus composition and / or an SLC agent. Additionally, the present invention provides a method for promoting the proliferation of a CD4 T cell, comprising administering to the cell an SLC agent in an amount effective to directly promote the proliferation of the cell. Finally, the present invention provides a method for treating or preventing a neoplasm or infectious disease in a subject using cultured CD4 T cells.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Serum-free media and their uses for chondrocyte expansion

The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential.
Owner:GENZYME CORP

Serum-free human amniotic mesenchymal stem cell culture medium and preparation method thereof

The invention provides a serum-free human amniotic mesenchymal stem cell culture medium, and belongs to the technical field of stem cells. The serum-free human amniotic mesenchymal stem cell culture medium comprises the following components: an IMDM basal culture medium, recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factors, platelet-derived growth factors, epidermal growth factors, insulin-like growth factors, transforming growth factors, fibronectin, fetuin, putrescine salt and recombinant human activin. The serum-free human amniotic mesenchymal stem cell culture medium provided by the invention does not need a culture bottle coating process, and is good in cell adherence and morphology and high in cell proliferation rate.
Owner:GUANGZHOU SALIAI STEMCELL SCI & TECH CO LTD

Corneal endothelial preparation which enables cells to grow in vivo

ActiveUS20100233240A1Small areaSuperior transplantationBiocideSenses disorderCorneal endothelial cellCorneal leucoma
The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which contains a substrate and a corneal endothelial cell layer cultured on the substrate, and a treatment method of a disease selected from the group consisting of bullous keratopathy, corneal edema, corneal leukoma and corneal endothelial inflammation, which includes a step of transplanting the preparation to patients. As the substrate, collagen is used.
Owner:SENJU PHARMA CO LTD

Composition for External Application

ActiveUS20170209522A1Superior collagen production promoting effectSuperior ability to promote cell proliferation cellCosmetic preparationsSenses disorderWrinkle skinExternal application
An object of the present invention is to provide an external use composition having a novel composition that has a superior effect promoting collagen production and is able to suppress, prevent or improve wrinkles and sagging of the skin with aging.The present invention relates to an external use composition for anti-aging, comprising (A) a lipopeptide represented by the following formula (1), or a pharmaceutically acceptable salt thereof:(wherein, R1 represents a saturated aliphatic group, or aliphatic group having a single unsaturated bond, having 9 to 19 carbon atoms, and m represents 0 or 1).
Owner:ROHTO PHARM CO LTD

Use of cb2 receptor agonists for promoting neurogenesis

InactiveUS20100004244A1Promoting and inducing and enhancing neurogenesisPromote cell proliferationBiocideNervous disorderAbnormal tissue growthCannabinoid Receptor CB2
The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries or damages to the CNS or the PNS associated with physical injury, ischemia, neurodegenerative disorders, certain medical procedures or medications, tumors, infections, metabolic or nutritional disorders, cognition or mood disorders, and various medical conditions associated with neural damage or destruction.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD

Collagen mimetic peptide

This disclosure relates to a novel Collagen Mimetic Peptide; a multi-arm conjugate comprising said peptide that mimics the higher order triple helical self-assembly of a collagen; a hydrogel comprising said Collagen Mimetic Peptide, optionally comprising collagen and optionally comprising a chemically modified surface; a corneal implant based on said hydrogel / modified hydrogel comprising a transparent central portion formed by an interpenetrating network comprising one or more additional biocompatible polymers wherein the central portion is adapted to remain cell free to ensure unhindered transmission of light.
Owner:UAB FERENTIS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products